This article aims to elucidate the prevalence of HER2 mutations and amplification in NSCLC, as well as the clinical characteristics and mutational profiles of patients with these alterations, based on retrospective analysis of diagnostic NGS performed at a referral center in Malaysia. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.